Marine Sponges and Bacteria as Challenging Sources of Enzyme Inhibitors for Pharmacological Applications

Nadia Ruocco 1,2,3, Susan Costantini 4, Flora Palumbo 5 and Maria Costantini 1,6,*

1 Department of Biology and Evolution of Marine Organisms, Stazione Zoologica Anton Dohrn, Villa Comunale, 80121 Napoli, Italy; nadia.ruocco@szn.it
2 Department of Biology, University of Naples Federico II, Complesso Universitario di Monte Sant’Angelo, Via Cinthia, 80126 Napoli, Italy
3 Bio-Organic Chemistry Unit, Institute of Biomolecular Chemistry-CNR, Via Campi Flegrei 34, Pozzuoli, 80078 Naples, Italy
4 Unità di Farmacologia Sperimentale, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, 80131 Napoli, Italy; susan.costantini@77@gmail.com
5 Department of Integrative Marine Ecology, Stazione Zoologica Anton Dohrn, Villa Comunale, 80121 Napoli, Italy; mcosta@szn.it
6 Institute of Biosciences and BioResources, CNR, 80131 Napoli, Italy
* Correspondence: maria.costantini@szn.it; Tel.: +39-081-583-3315; Fax: +39-081-764-1355

Received: 5 May 2017; Accepted: 8 June 2017; Published: 12 June 2017

Abstract: Enzymes play key roles in different cellular processes, for example, in signal transduction, cell differentiation and proliferation, metabolic processes, DNA damage repair, apoptosis, and response to stress. A deregulation of enzymes has been considered one of the first causes of several diseases, including cancers. In the last several years, enzyme inhibitors, being good candidates as drugs in the pathogenic processes, have received an increasing amount of attention for their potential application in pharmacology. The marine environment is considered a challenging source of enzyme inhibitors for pharmacological applications. In this review, we report on secondary metabolites with enzyme inhibitory activity, focusing our attention on marine sponges and bacteria as promising sources. In the case of sponges, we only reported the kinase inhibitors, because this class was the most representative isolated so far from these marine organisms.

Keywords: enzyme inhibitors; sponges; bacteria

1. An Introduction to Enzyme Inhibitors in Marine Environments

An important challenge of the last several decades has been the search for active compounds from natural sources, about 50% of which have pharmacological applications [1,2].

Among natural compounds, enzyme inhibitors have been considered useful tools mainly for their biotechnological potential in pharmacology [3] and agriculture [4]. In particular, protease inhibitors represent important examples of enzyme inhibitors, able to inactivate target proteases in the presence of human diseases (as for example in high blood pressure, arthritis, muscular dystrophy, pancreatitis, thrombosis, different cancers, as well as AIDS [5,6]). In the case of carbohydrate-dependent diseases, such as diabetes, obesity and hyperlipemia, amylase inhibitors represent useful tools for controlling them [7,8]. Enzyme inhibitors have been also isolated from different terrestrial organisms, including microorganisms (mainly actinomycetes; [9]), even if they are able to produce structurally identical inhibitors [10]. Differently, in the marine organisms occurs considerably different characteristics of enzyme inhibitors in comparison with the terrestrial ones [11].
In fact, the oceans (covering 70% of the earth) represent a widely unexplored and promising source of new biologically active natural compounds, also linked to the highest biodiversity of the marine environment in comparison with the terrestrial one [12–16]. Concerning the marine environment, it is important to consider that sessile marine invertebrates, such as sponges, cnidaria, and ascidians, constitute the largest amount of biomass of the marine macrofauna. They are able to store several secondary metabolites for their ecological success in different marine habitats so as to counterattack predation and pathogenic organisms [17–20]. These chemical defenses of sessile marine invertebrates not only have ecological roles but also exhibit several different biological activities with pharmacological, nutraceutical, and cosmeceutical applications [13,21–23].

Marine microorganisms isolated for the first time in the marine environment in the last century are another key source of active natural compounds. In more detail, marine microorganisms are very different from terrestrial ones, for their metabolic and physiological processes, because about 90% of them are Gram-negative psychrophiles that also require high Na\(^+\) concentration for growth [24,25]. Maeda and Taga [25] isolated a deoxyribonuclease from a marine Vibrio sp. and studied its activity, demonstrating that this enzyme was activated by Mg\(^{2+}\) and stabilized by Ca\(^{2+}\). Moreover, another marine bacterium has been isolated, able to produce a phosphatase with its activity at a high level of hydrostatic pressure (1000 atm; [26]), suggesting that marine enzymes acted in a different way in comparison to terrestrial ones. Moreover, many enzymes have significant roles in the maintenance of homeostasis and diseases are the results of the breakdown of homeostasis. In fact, there is a very strong correlation between the biological functions of several enzymes and diseases. Enzyme inhibitors are molecules that reduce the catalytic activity or the complete blocking of enzymes, thus causing either the complete cell death or modification in the pathways. On this line, some enzyme inhibitors correlated with specific diseases are very important as drugs [27]. For example, the angiotensin-converting enzyme (ACE) inhibitors act as antihypertensive drugs, reducing hypertension. Adenosine deaminase inhibitors alter adenosine and deoxyadenosine levels together with lymphocytic growth and function, thus enhancing the chemotherapeutic effects of adenoside analogs in cancer chemotherapy [28].

Taking this into account, this review reports examples of many enzyme inhibitors from marine microorganisms with pharmaceutical significance. In particular, we report on two important sources of enzyme inhibitors from the marine environment: the sponges and the bacteria. In the case of sponges, we will only focus our attention on the kinase inhibitors since this class is the most representative that has so far been isolated from these marine organisms.

### 2. Marine Sponges

Although marine sponges are considered very simple marine organisms, they represent “chemical factories” because they are able to produce a great number of biologically active compounds [29]. There is still an ongoing debate about whether natural products isolated from sponges originated from sponges or from associated bacteria. Several experiments have evidenced that some compounds isolated from sponges are synthesized by their associated microorganisms [15,30]. In the case of enzyme inhibitors, there are also several evidences on their bacterial origin (see below).

Polyketides, terpenoids, and peptides are the most abundant products isolated from sponges, showing inhibitory activities against many enzymes (Figure 1; see also Figures 2–4 for the chemical structures of enzyme inhibitors reported in this paragraph).

Recently, the alkylpyridinium salts have been isolated from sponges, showing potent biological activities mainly as enzyme inhibitors. The marine sponge *Reniera sarai* produce some polymeric 3-alkylpyridinium salts [29]. Cyclostelletamines, cyclic pyridinium alkaloids, from the sponge *Stelletta maxima* [31] are able to inhibit the reaction of methyl quinuclidinyl benzilate with muscarinic acetylcholine receptors. The sponge *Callyspongia fibrosa* is the source of some polymers, which inhibit the epidermal growth factors [32]. Among acetylcholinesterase (AChE) inhibitors, an irreversible inhibitor (the onchidal) has been isolated from the mollusk *Onchidella binneyi* [33], and a pseudozoanthoxanthin-like compound from the coral *Parazoanthus axinellae* [34].
Figure 1. Enzyme inhibitors isolated from marine sponges.

The enzyme adenine phosphoribosyl transferase of Leishmania tarentolae (L-APRT) has been inhibited by crude extracts from several marine invertebrates, as for example from the ascidian Polysyncraton sp. and from the bryozoan Bugula sp. [35]. Concerning the sponges, an inhibitor of L-APRT activity has been found in Dragmacidon sp. and Polymastia sp. The haplosclerid Callyspongia sp. SS97-23 was the source of three meroterpenoids, ilhabelanol, ilhabeiren, and isoakaterpin, very potent inhibitors of L-APRT [36]. The marine sponge Petromica sp. BA99-103 produced halistanol sulfate, another inhibitor of L-APRT [35].

Marine sponges have been also proven as sources of protein kinase (PK) inhibitors. The enzymes, belonging to the protein kinase family, chemically catalyzed the transfer of a phosphate group to a defined substrate from a high-energy molecule. About 2% of all eukaryotic genes are protein kinases, organized in eight main groups [37]: (1) TK (tyrosine kinase); (2) TKL (tyrosine kinase-like); (3) STE (STE20, STE11, and STE7); (4) CK1 (casein kinase 1); (5) AGC (protein kinase A, protein kinase G, and protein kinase C); (6) CAMK (Ca\(^{2+}\) / calmodulin-dependent kinases); (7) CMGC (Cdk, MAPK, GSK, Cdk-like); (8) RGC (receptor guanylyl cyclase). Kinases play key roles in different regulatory cellular processes, signal transduction, cell proliferation and differentiation, metabolic processes, apoptosis, and so on [2,38]. Because of the very different roles of the kinases, several diseases have as causes the deregulation of these enzymes. Furthermore, misregulation of various kinases has very often been reported in cancerous cells, so anticancer treatments involve kinases to specifically target cancer cells [39]. Kinase inhibitors represented a good challenge for cancer treatments, considering that to date about 130 kinase inhibitors are in different phases of clinical trials [40]. This is the case, for example, of Imitinib (Gleevec, Novartis), a tyrosine kinase inhibitor used in the prognosis for sufferers of chronic myeloid leukemia, now in the pharmaceutical market [41]. Inhibitors for different PK isolated from marine sponges are reported below (Table 1).

PKC inhibitors (serine/threonine kinases involved in cell differentiation, apoptosis, and inhibition cancer, Figure 2):

- xestocyclamine A (1), from Xestospongia sp. from Papua New Guinea coast, used for the development of drugs in anticancer therapy [42–44];
- (Z)-Axinohydantoin (2) and debromo-Z-axinohydantoin, from Stylorella aurantium [45];
- five sesquiterpene derivatives, frondosins A–E (frondosin A (3) in Figure 1) from Dysidea frondosa. Frondosins A–E were inhibitors of interleukin-8, whereas frondosins A and D also have activity against the HIV virus [46];
- BRS1, a lipid from a calcarea sponge [47];
- nakijiquinones A–D, sesquiterpenoid quinones, from a Spongiidae [48,49], exerting also inhibitory activity against HER2 kinase and epidermal growth factor receptor (EGFR) [50];
- lasonolide A (4), from Forcepsia sp., used against mouse thymoma cells [51–53];
- spongianolides A–E (spongianolide A (5) in Figure 2), sesterpenes, from the genus Spongia [54];
- penazetidine A (6), new azetidine compound from *Penares sollasi*, cytotoxic against human and murine cancer cell lines (A549, HT-29, B16/F10 and P388) [55];
- corallidictyals A (7) and B, two diastereomeric spirosesquiterpene aldehydes, from *Aka coralliphaga* [56], selectively inhibiting the α-PKC isoform.

Table 1. Kinase enzyme, enzyme inhibitors names (together with number compounds in the case the chemical structure have been reported in Figures 2–5), references, pharmacological applications, and IC50 values (in micromolar, µM) from marine sponges: the four less potent enzyme inhibitors were indicated with (*), the five more potent with (**).
Figure 2. Chemical structures of some natural PKC and CDK inhibitors isolated from sponges, reported as examples.

Cyclin-dependent kinases (CDK) inhibitors (serine/threonine kinases, involved in the regulation of the cell cycle; Figure 2):
CDK-1 (mitosis phase)

- hymenialdisine (8), from Axinella verrucosa and Acanthella aurantiaca, able to act on NF-kappa B signaling process and indicated as possible pharmaceuticals in treating rheumatoid arthritis, multiple sclerosis, and Alzheimer’s diseases by some recent patents [57];
- microxine (9), a purine derivative from genus Microxina [58];
- variolin B (10), from the Antarctic Kirkpatrickia variolosa, able to inhibit the phosphorylation process of histone H1 [59,60].

CDK-4 (G1 phase)

- fascaplysin (11), a red pigment isolated from Fascaplysinopsis sp. It is a potent inhibitor of angiogenesis, inhibiting the proliferation of endothelial cells through VEGF [61].
- konbu’acidin A (12), a bromopyrrole alkaloid from the Okinawan Hymeniacidon sp. [62];
- two quinols and halistanol sulfate (13), novel sesquiterpene, from Aka sp. [63];

Tyrosine protein kinase (TPK) inhibitors (involved in the phosphorylation of tyrosine residues in proliferative diseases; Figure 3):

- the penta-, hexa-, and hepta-prenylhydroquinone 4-sulfates (14), from the deep-sea Ircinia sp. [64], with cytotoxic activity against HIV-1 integrase enzyme and epidermal carcinoma cell line;
- melemeleone (15), a novel sesquiterpene, from two species of Dysidea, with activity against tyrosine kinase pp60V-SRC [65];
- halenaquinone (16), halenaquinol, halenaquinol sulfate, and xestoquinone from Xestospongia carbonaria [66].

Epidermal growth factor receptor (EGFR) inhibitors (tyrosine kinases involved mainly in breast cancer; Figure 3):

- tauroacidins A (17) and B, bromopyrrole alkaloids from Hymeniacidon sp. [67];
- ma’edamine A (18), bromotyrosine alkaloid, from Suberea sp. [68];
- spongiacidins A (19) and B, bromopyrrole alkaloids from Hymeniacidon sp. [69];
- (+)-aeroplysinin-1 (20), from Verongia aerophoba, antitumoral on EGFR-dependent human breast cancer cell lines MCF-7 and ZR-75-1 [70];
- butyrolactone derivative (21), from Acanthella cavernosa [71];
- 3-norspongiolactone (22) and gracilins J–L (23), bioactive diterpenes from Spongionella sp. [72].

Mitogen-activated protein kinase (MK) inhibitors (serine/threonine protein kinases associated to stress; Figure 4):

- cheilanthane sesterterpenoid (24), from Ircinia sp. [73] and extracts from lotrotchota birotulata and Spongia barbara [74];
- hymenin (25) and hymenialdisine (27), from Stylostella aurantium [75];
- a methanol fraction from Batzella sp. [76];
- onnamide A (28), heterocyclic compounds belonging to pederin family from Theonella swinhoei. Its activity is through the stimulation of plasminogen activator inhibitor-1 (PAI-1) considered a drug target against metastasis in human cancer cells [77];
- (+)-makassaric acid (26) and (+)-subersic acid (29), meroterpenoids from Acanthodendrilla sp., acting inflammatory responses and cellular stress processes [78].

Glycogen synthase kinase-3 (GSK-3) inhibitors (a serine/threonine protein kinase, involved in neurodegenerative diseases; Figure 4):

- manzamine A (30), an alkaloid from the genus Haliclona [79], agent against the growth of the malaria parasite Plasmodium berghei [80].
Other kinases inhibitors (Figure 4)

- liphagal (31), a meroterpenoid from *Aka coralliphaga*, with inhibitory activity against PI3K and cytotoxic against human colon and human breast cancer [81];
- (+)-curcuphenol (32) (Src protein kinase inhibitor) and (+)-curcudiol (33) (focal adhesion kinase, FAK, inhibitor), two bisabolenes type sesquiterpenoids *Axynissa* sp. [82];
- (34) homogenetic acid from *Pseudoceratina* against protein kinase of *Plasmodium falciparum* [83];
- hymenialdisine, debromohymenialdisine, and four novel dihydrohymenialdisine derivatives from *Cymbastela cantharella*, able to inhibit the Polo-Like kinase-1 [84].

**Figure 3.** Chemical structure of some natural TPK and EGFR inhibitors isolated from sponges, reported as examples.
Figure 4. Chemical structure of some natural mitogen-activated protein kinase (MK) and GSK-3 inhibitors and other kinases inhibitors isolated from sponges, reported as examples.

3. Marine Bacteria

In the marine environment, several enzyme inhibitors have been isolated from bacteria and actinomycetes for their industrial applications and their use in medicine and agriculture [11] (see Figure 5).

Figure 5. Enzyme inhibitors isolated from marine bacteria.
One of the first isolated marine microbial source of enzyme inhibitors were represented by the Alteromonas sp., from which serine and cysteine protease inhibitors have been isolated [85]. An example of serine protease inhibitors are represented by the marinostatins C-1 and C-2, used as drugs in pancreatitis pathogenesis thanks to its properties to inhibit α-chymotrypsin (IC\(_{50}\) = 1.0–3.2 µM) [86,87].

Inhibitors for different PK isolated from marine bacteria are summarized in Table 2.

Some examples of the chemical structures of enzyme inhibitors from marine bacteria are reported in Figure 6:

- endogenous monoamine oxidase (MAO) inhibitors, the 2,3-indolinedione (35), from marine Alteromonas sp., increasing the acetylcholine and dopamine in neurotransmission processes (IC\(_{50}\) = 9.2 µM) [88].
- monastatin, a glycoprotein from pathogenic fish bacteria such as Aeromonas hydrophila and Vibrio anguillarum [89]. It has been applied in the production of cooked fish meat gel [90].
- B-90063 (36), endothelin-converting enzyme (ECE) inhibitor from Blastobacter sp. SANK 71894, (IC\(_{50}\) = 1.0–3.2 µM) [91], able to cause blood vessel contraction and for this reason applied in hypertension, cardiovascular, and renal diseases [92].
- pyrostatins A (37) and B (38), from the Streptomyces strain SA-3501, (IC\(_{50}\) = 1.0 µM), with inhibitory activity against N-acetyl-b-D-glucosaminidase (GluNAc-ase; [93]), applied as drugs in diabetes [94], leukemia [95], and cancer [96].
- pyrizinostatin (40), inhibitor of pyroglutamyl peptidase (PGP) from a Streptomyces strain (IC\(_{50}\) = 21 µM) [97], able to block thyrotropin-releasing and luteinizing hormone-releasing hormones [98].
- CI-4 (39) (cyclo(-Arg-D-Pro; [99,100]), a chitinase inhibitor from Pseudomonas sp., a useful source for antifungal and insecticidal agents [101].
- angiotensin-converting enzyme (ACE) inhibitors and adenosine deaminase inhibitors (ADA) [27], from different Streptomyces strains. ACE inhibitors were able to reduce hypertension either by the suppression of angiotensin II biosynthesis or by the stimulation of bradykinin breakdown; ADA inhibitors were responsible for the alteration in adenosine and deoxyadenosine levels and in lymphocytic growth and functions, and enhance the effects of chemotherapeutic effects of adenosine analogs. Among 94 Streptomyces strains screened, 8 and 4 strains were positive for ACE and ADE inhibitors, respectively [27].
- hydroxyakalone (41), an inhibitor of xanthine oxidase (XO), from the fermentation broth of Agrobacterium aurantiacum sp. (IC\(_{50}\) = 4.6 µM) [102], used as a drug in diseases caused by an accumulation of uric acid [103].

Table 2. Enzyme, enzyme inhibitors names (together with number compounds in the case the chemical structure have been reported in Figure 6), references, biotechnological applications, and IC\(_{50}\) values (in micromolar, µM) from marine bacteria.

| Kinase Enzyme | Compound | Reference | Application | IC\(_{50}\) (µM) |
|---------------|----------|-----------|-------------|-----------------|
| Serine protease | marinostatins C1–C2 | [86,87] | pancreatitis pathogenesis | 1.0–3.2 |
| Monoamine oxidase | 2,3-indolinedione (35) | [88] | neurodegenerative diseases | 9.2 |
| Protease | monostatin | [89,90] | cooked fish meat gel | |
| ECE | B-90063 (36) | [92] | hypertension, renal disease | 1.0–3.2 |
| GluNAc-ase | pyrostatins A–B (37,38) | [93–96] | diabetes, leukemia, cancer | 1 |
| PGP | pyrizinostatin (40) | [97,98] | hormone diseases | 21 |
| Chitinase | CI-4 (39) | [99–101] | antifungal and insecticidal | |
| Xanthine oxidase | hydroxyakalone (41) | [102,103] | uric acid accumulation | 4.6 |

Recently, the actinobacteria have also been considered as producers of enzyme inhibitors. This is the case for 30 strains of marine actinobacteria reported by Ganesan et al. [104], used in treating diabetes.
Marine bacteria associated with the sponge *Jaspis* sp. have been characterized for their production of protease inhibitors [105]. In particular, the associated bacteria *Providencia* sp. showed inhibitory activity against the protease subtilisin, and *Bacillus* sp. had inhibitory effects against the metalloproteinase thermolysin.

### 4. General Conclusions

The increased incidence of severe diseases, including cancer, prompted the scientific research to find new drugs. This also pushed the scientific communities to explore the marine environment for new pharmaceuticals. In fact, the marine environment has a great richness and biodiversity of micro- and macroorganisms, also exhibiting biosynthetic pathways to produce secondary metabolites useful both against predators and active compounds for human health attracting the attention of pharmaceutical industries. A very significant example is represented by several classes of enzyme inhibitors isolated from marine sponges and bacteria, as reported in the review. These enzyme inhibitors show cytotoxic activity against many different cancer cell lines (see Table 1). Marine-derived enzyme inhibitors are
considered viable alternatives in pharmaceuticals for replacing synthetic drugs to combat, for example, cancer as well as viral, antiinflammatory, and neurodegenerative diseases. Nonetheless, further studies will be necessary to investigate the human consumer’s well being. The general significance of the topic of this review is well underlined by the number of EU-funded projects, as well as by Horizon 2020, which are aimed at improving the exploitation of marine organisms for drug discovery.

Acknowledgments: Nadia Ruocco (Ph.D. in Biology, University of Naples Federico II) was supported by a Ph.D. fellowship co-funded by the Stazione Zoologica Anton Dohrn and Bio-Organic Chemistry Unit of the Institute of Biomolecular Chemistry-CNR, Pozzuoli, Naples, Italy.

Author Contributions: M.C., N.R. and S.C. conceived and designed the scheme of the review and wrote the paper. F.P. created the illustrations in the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. *J. Nat. Prod.* 2007, 70, 461–477. [CrossRef] [PubMed]
2. Skropeta, D.; Pastro, N.; Zivanovic, A. Kinase inhibitors from marine sponges. *Mar. Drugs* 2011, 9, 2131–2154. [CrossRef] [PubMed]
3. Bode, W.; Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases. *Eur. J. Biochem.* 1992, 204, 433–451. [CrossRef] [PubMed]
4. Terashita, T.; Kono, M.; Murao, S. Promoting effect of S-PI on fruiting of *Lentinus edodes*. *Trans. Mycol. Soc. Jpn.* 1980, 21, 137–140.
5. Demuth, H.U. Recent developments in inhibiting cysteine and serine proteases. *J. Enzym. Inhib.* 1990, 3, 249–278. [CrossRef] [PubMed]
6. Delston, R.B.; Kothary, M.H.; Shangraw, K.A.; Tall, B.D. Isolation and characterization of a zinc-containing metalloprotease expressed by *Vibrio tubiashi*. *Can. J. Microbiol.* 2003, 49, 525. [CrossRef] [PubMed]
7. Bo-Linn, G.W.; Santa Ana, C.A.; Morawski, S.G.; Fordtran, J.S. Starch blockers—their effect on calorie absorption from a high-starch meal. *N. Engl. J. Med.* 1982, 307, 1413–1416. [CrossRef] [PubMed]
8. Puls, W.; Keup, U. Influence of an α-amylase inhibitor (BAY d 7791) on blood glucose, serum insulin and NEFA in starch loading tests in rats, dogs and man. *Diabetologia* 1973, 9, 97–101. [CrossRef] [PubMed]
9. Umezawa, H. *Enzyme Inhibitor of Microbial Origin*; University of Tokyo Press: Tokyo, Japan, 1972.
10. Hamato, N.; Kamei-Hayashi, T.; Imada, C.; Hara, S. Leupeptins produced by the marine *Alteromonas* sp. B-10-31. *Biosci. Biotechnol. Biochem.* 1992, 56, 1316–1318. [CrossRef]
11. Imada, C. Enzyme inhibitors of marine microbial origin with pharmaceutical importance. *Mar. Biotechnol.* 2004, 6, 193–198. [CrossRef] [PubMed]
12. Aneiros, A.; Garateix, A. Bioactive peptides from marine sources: Pharmacological properties and isolation procedures. *J. Chromatogr. B. Anal. Technol. Biomed. Life Sci.* 2004, 15, 41–53. [CrossRef] [PubMed]
13. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2012, 29, 144–222. [CrossRef] [PubMed]
14. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2014, 31, 160–258. [CrossRef] [PubMed]
15. Mehbub, M.F.; Lei, J.; Franco, C.; Zhang, W. Marine sponge derived natural products between 2001 and 2010: Trends and opportunities for discovery of bioactives. *Mar. Drugs* 2014, 12, 4539–4577. [CrossRef] [PubMed]
16. Reen, F.; Gutierrez-Barranquero, J.; Dobson, A.; Adams, C.; O’Gara, F. Emerging concepts promising new horizons for marine biodiscovery and synthetic biology. *Mar. Drugs* 2015, 13, 2924–2954. [CrossRef] [PubMed]
17. Amsler, C.D.; Iken, K.B.; McClintock, J.B.; Baker, B.J. Secondary metabolites from Antarctic marine organisms and their ecological implications. In *Marine ChemicalEcology*; McClintock, J.B., Baker, J.B., Eds.; CRC Press: Boca Raton, FL, USA, 2001; pp. 267–300.
18. Lindquist, N. Chemical defense of early stages of benthic marine invertebrates. *J. Chem. Ecol.* 2002, 28, 1987–2000. [CrossRef] [PubMed]
19. Blunt, J.W.; Copp, B.R.; Hu, W.P.; Munro, M.H.; Northcote, P.T.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2007, 24, 31–86. [CrossRef] [PubMed]

20. Faulkner, D.J. Marine pharmacology. *Antonie Leeuwenhoek* 2000, 77, 135–145. [CrossRef] [PubMed]

21. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2013, 30, 237–323. [CrossRef] [PubMed]

22. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2015, 32, 116–211. [CrossRef] [PubMed]

23. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2016, 33, 382–431. [CrossRef] [PubMed]

24. MacLeod, R.A. On the role of inorganic ions in the physiology of marine bacteria, VI. In *Advances in Microbiology of the Sea*; Droop, M.R., Wood, E.J.F., Eds.; Academic Press: New York, NY, USA, 1968; Volume 1, pp. 95–126.

25. Maeda, M.; Taga, N. Extracellular nuclease produced by a marine bacterium, II: Purification and properties of extracellular nuclease from a marine *Vibrio* sp. *Can. J. Microbiol.* 1976, 22, 1443–1452. [CrossRef]

26. Kobori, H.; Taga, N. Extracellular alkaline phosphatase from marine bacteria: Purification and properties of extracellular phosphatase from a marine *Pseudomonas* sp. *Can. J. Microbiol.* 1980, 26, 833–838. [CrossRef]

27. Chellaram, C.; Prem Anand, T.; Felicia Shanthini, C.; Chandrika, M.; Gladis, C. Screening for enzyme inhibitors in marine bacteria. *Int. J. PharmTech Res.* 2014, 6, 351–355.

28. Agarwal, R.P. Inhibitors of adenosine deaminase. *Pharmacol. Ther.* 1982, 17, 399–429. [CrossRef]

29. Sepčić, K.; Marcel, V.; Klaebe, A.; Turk, T.; Šuput, D.; Fournier, D. Inhibition of acetylcholinesterase by a pseudozoanthoxanthin-like compound which inhibit binding of methyl quinuclidinyl benzilate (QNB) to muscarinic acetylcholine receptors, from the marine sponge, *Stelletta maxima*. *Biochim. Biophys. Acta* 1998, 1387, 217–225. [CrossRef]

30. Lee, Y.K.; Lee, J.-H.; Lee, H.K. Microbial symbiosis in marine sponges. *J. Microbiol.* 2001, 39, 254–264.

31. Fusetani, N.; Asai, N.; Matsunaga, S.; Honda, K.; Yasumuro, K. Cyclostellettamines A–F, pyridine alkaloids from the sponge, *Callyspongia fibrosa*. *J. Org. Chem.* 1995, 60, 349–354. [PubMed]

32. Davies-Coleman, M.T.; Faulkner, J.; Dubowchik, G.; Roth, G.P.; Polson, C.; Fairchild, C. A new EGF-active polymeric pyridinium alkaloid from the marine sponge, *Callyspongia fibrosa*. *J. Org. Chem.* 1993, 58, 5925–5930. [CrossRef]

33. Abramson, S.N.; Radic, Z.; Manker, D.; Faulkner, J.; Taylor, P. Onchidal: A naturally occurring irreversible inhibitor of acetylcholinesterase with a novel mechanism of action. *Mol. Pharmacol.* 1989, 36, 349–354. [PubMed]

34. Arief, P.; Macleod, R.A. On the role of inorganic ions in the physiology of marine bacteria, VI. In *Advances in Microbiology of the Sea*; Droop, M.R., Wood, E.J.F., Eds.; Academic Press: New York, NY, USA, 1968; Volume 1, pp. 95–126.

35. Duong-Ly, K.C.; Peterson, J.R. The human kinome and kinase inhibition. *Curr. Protoc. Pharmacol.* 2013. [CrossRef]

36. Novak, K. Conference report—protein kinase inhibitors in cancer treatment: Mixing and matching? In Proceedings of the Keystone Symposium on Protein Kinases and Cancer, Medscape General Medicine, Lake Tahoe, CA, USA, 24–29 February 2004.

37. Goldstein, D.; Gray, N.; Zarrinkar, P. High-throughput kinase profiling as a platform for drug discovery. *Nat. Rev. Drug Discov.* 2008, 7, 391–397. [CrossRef] [PubMed]
42. Rodriguez, J.; Peters, B.M.; Kurz, L.; Schatzman, R.C.; McCarley, D.; Lou, L.; Crews, P. An alkaloid protein kinase C inhibitor, xestocyclamine A, from the marine sponge *Xestospongia* sp. *J. Am. Chem. Soc.* 1993, 115, 10436–10437. [CrossRef]
43. Rodriguez, J.; Crews, P. Revised structure of xestocyclamine A and description of new analogue. *Tetrahedron Lett.* 1994, 35, 4719–4722. [CrossRef]
44. Yun, H.; Gagnon, A.; Danishefsky, S.J. Toward the synthesis of xestocyclamine A: Investigation of double Michael reaction and directaza Diels-Alder reaction. *Tetrahedron Lett.* 2006, 47, 5311–5315. [CrossRef]
45. Patil, A.D.; Freyer, A.J.; Killmer, L.; Hofmann, G.; Johnson, R.K. *Z*-Axinohydantoin and debromo-*Z*-axinohydantoin from the sponge *Stylotella aurantium*: Inhibitors of protein kinase C. *Nat. Prod. Res.* 1997, 9, 201–207.
46. Freyer, A.J.; Patil, A.D.; Killmer, L.; Oden, P.; Carte, B.; Jurewicz, A.J.; Johnson, R.K. Frondosins, five new sesquiterpene hydroquinone derivatives with novel skeletons from the sponge *Dysidea frondosa*: Inhibitors of interleukin-8 receptors. *Tetrahedron* 1997, 53, 5047–5060.
47. Willis, R.H.; de Vries, D.J. BR51, a C30 bis-amino, bis-hydroxy polyunsaturated lipid from an Australian calcareous sponge that inhibits protein kinase C. *Toxicon* 1997, 35, 1125–1129. [CrossRef]
48. Shigemori, H.; Madono, T.; Sasaki, T.; Mikami, Y.; Kobayashi, J. Nakijiquinones A and B, new antifungal sesquiterpenoid quinones with an amino acid residue from an Okinawan marine sponge. *Tetrahedron* 1994, 50, 8347–8354. [CrossRef]
49. Kobayashi, J.; Madono, T.; Shigemori, H. Nakijiquinones C and D, new sesquiterpenoid quinones with activity from *Hymeniacidon* sponge. *Tetrahedron* 1997, 53, 4719–4722. [CrossRef]
50. Kissau, L.; Stahl, P.; Mazitschek, R.; Giannis, A.; Waldmann, H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. *J. Med. Chem.* 1994, 37, 2917–2931. [CrossRef] [PubMed]
51. Horton, P.A.; Koehn, F.E.; Longley, R.E.; McConnell, O.J. Lasonolide A, a new cytotoxic macrolide from the marine sponge *Siphonodictyon coralliphagum*. *J. Nat. Prod.* 2000, 63, 7189–7192. [CrossRef] [PubMed]
52. Isbrucker, R.A.; Guzman, E.A.; Pitts, T.P.; Wright, A.E. Early effects of lasonolide A on pancreatic cancer cells. *J. Pharmacol. Exp. Ther.* 2009, 329, 733–739. [CrossRef] [PubMed]
53. Kobayashi, J.; Suzuki, M.; Tsuda, M. Konbu’acidin A, a new bromopyrrole alkaloid with cdk4 inhibitory activity from *Stylotella aurantium*. *Chem. Res. Commun.* 2000, 275, 877–884. [CrossRef] [PubMed]
54. He, H.; Kulanthaivel, P.; Baker, B.J. New cytotoxic sesterterpenes from the marine sponge *Spongia* sp. *Tetrahedron Lett.* 1994, 35, 7189–7192. [CrossRef]
55. Alvi, K.A.; Jaspars, M.; Crews, P.; Strulovici, B.; Oto, E. Penazetidine-A, an alkaloid inhibitor of protein kinase C. *Bioorg. Med. Chem. Lett.* 1994, 4, 2447–2450. [CrossRef]
56. Chan, J.A.; Freyer, A.J.; Carte, B.K.; Hemling, M.E.; Hofmann, G.A.; Mattern, M.R.; Mentzer, M.A.; Westley, J.W. Protein kinase C inhibitors: Novel spirosesterepene aldehydes from a marine sponge *Aka (=Siphonodictyon) coralliphagum*. *J. Nat. Prod.* 1994, 57, 1543–1548. [CrossRef] [PubMed]
57. Meijer, L.; Thunnissen, A.M.; White, A.W.; Garnier, M.; Nikolic, M.; Tsai, L.H.; Walter, J.; Cleverley, K.E.; Salinas, P.C.; Wu, Y.Z.; et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hynemialdisine, a marine sponge constituent. *Chem. Biol.* 2000, 7, 51–63. [CrossRef]
58. Killday, B.; Yarwood, D.; Sills, M.; Murphy, P.; Hooper, J.; Wright, A. Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge *Microspongia* species. *J. Nat. Prod.* 2001, 64, 525–526. [CrossRef] [PubMed]
59. Trimurtulu, G.; Faulkner, D.J.; Perry, N.B.; Ettouati, L.; Litaudon, M.; Blunt, J.W.; Munro, M.H.G.; Jameson, G.B. Alkaloids from theantarctic sponge *Kirkpatrickia varialosa*. Part 2: Variolin A and N(3)-methyltetrahydrovariolin B. *Tetrahedron* 1994, 50, 3993–4000. [CrossRef]
60. Walker, S.R.; Carter, E.J.; Huff, B.C.; Morris, J.C. Variolins and related alkaloids. *Chem. Rev.* 2009, 109, 3080–3098. [CrossRef] [PubMed]
61. Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fapsedycasin, a marine natural product. *Biochem. Biophys. Res. Commun.* 2000, 275, 877–884. [CrossRef] [PubMed]
Mar. Drugs 2017, 15, 173

63. Mukku, V.; Edrada, R.A.; Schmitz, F.J.; Shanks, M.K.; Chaudhuri, B.; Fabbro, D. New sesquiterpene quinols from a micronesian sponge, *Aka* sp. *J. Nat. Prod.* 2003, 66, 686–689. [CrossRef] [PubMed]

64. Bifulco, G.; Bruno, I.; Minale, L.; Riccio, R.; Debitus, C.; Bourdy, G.; Vassas, A.; Lavayre, J. Bioactive prenylhydroquinone sulfates and a novel C31 furanoterpenic alcohol sulfate from the marine sponge, *Ircinia* sp. *J. Nat. Prod.* 1995, 58, 1444–1449. [CrossRef]

65. Alvi, K.A.; Diaz, M.C.; Crews, P.; Slate, D.L.; Lee, R.H.; Moretti, R. Evaluation of new sesquiterpene quinones from two *Dysidea* sponge species as inhibitors of protein tyrosine kinase. *J. Org. Chem.* 1992, 57, 6604–6607. [CrossRef]

66. Lee, R.H.; Slate, D.L.; Moretti, R.; Alvi, K.A.; Crews, P. Marine sponge polyketide inhibitors of protein tyrosine kinase. *Biochem. Biophys. Res. Commun.* 1992, 184, 765–772. [CrossRef]

67. Kobayashi, J.; Inaba, K.; Tsuda, M. Tauroacidins A and B, new bromopyrrole alkaloids possessing a taurine residue from hymeniadicon sponge. *Tetrahedron* 1997, 53, 16679–16682. [CrossRef]

68. Kobayashi, J.; Hirano, K.; Kubota, T.; Tsuda, M.; Watanabe, K.; Fromont, J. Ma’edamines A and B, cytotoxic bromotyrosine alkaloids with a unique 2(1H)pyrazinone ring from sponge *Suberea* sp. *Tetrahedron* 2000, 56, 8107–8110.

69. Inaba, K.; Sato, H.; Tsuda, M.; Kobayashi, J. Spongicadins A–D, new bromopyrrole alkaloids from hymeniadicon sponge. *J. Nat. Prod.* 1998, 61, 693–695. [CrossRef] [PubMed]

70. Kreuter, M.-H.; Leake, R.E.; Rinaldi, F.; Müller-Klieser, W.; Maidhof, A.; Müller, W.E.G.; Schröder, H.C. Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* 1990, 97, 151–158. [CrossRef]

71. Rateb, M.E.; Houssen, W.E.; Legrave, N.M.; Clements, C.; Jaspars, M.; Ebel, R. Dibenzo[fg]furans from the marine sponge-derived ascomycete SuperF1-09. *Bot. Mar.* 2010, 53, 499–506. [CrossRef]

72. Rateb, M.E.; Houssen, W.E.; Schumacher, M.; Harrison, W.T.A.; Diederich, M.; Ebel, R.; Jaspars, M. Bioactive diterpene derivatives from the marine sponge *Spongionella* sp. *J. Nat. Prod.* 2009, 72, 1471–1476. [CrossRef] [PubMed]

73. Buchanan, M.S.; Edser, A.; King, G.; Whitmore, J.; Quinn, R.J. Cheilanthane sesterterpenes, protein kinase inhibitors, from a marine sponge of the genus *Ircinia*. *J. Nat. Prod.* 2001, 64, 300–303. [CrossRef] [PubMed]

74. Brown, J.; Kesler, C.; Neary, J.; Fishman, L. Effects of marine sponge extracts on mitogen-activated protein kinase. *Biochem. Biophys. Res. Commun.* 1992, 184, 765–772. [CrossRef]

75. Tasdemir, D.; Mallon, R.; Greenstein, M.; Feldberg, L.; Kim, S.; Collins, K.; Wojciechowicz, D.; Mangalindan, G.; Concepcion, G.; Harper, M.K.; et al. Aldisine alkaloids from the Philippine sponge *Stylissa massa* are potent Inhibitors of mitogen-activated protein kinase-1 (MEK-1). *J. Med. Chem.* 2002, 45, 529–532. [CrossRef] [PubMed]

76. Freitas, J.; Malpezzi, E.; Costa, L.; Berlinck, R.; Almeida, A.; Ogawa, C.; Sanchez, M.; Hajdu, E. Cytotoxic and neurotoxic effects induced by halitoxin isolated from *Dysidea* spp. *Toxicon* 1996, 34, 335. [CrossRef]

77. Lee, K.H.; Nishimura, S.; Matsunaga, S.; Fusetani, N.; Horinouchi, S.; Yoshih, M. Inhibition of protein synthesis and activation of stress-activated protein kinases by onnamide A and theopederin B, antitumor marine natural products. *Cancer Sci.* 2005, 96, 357–364. [CrossRef] [PubMed]

78. Williams, D.E.; Telliez, J.B.; Liu, J.; Tahir, A.; van Soest, R.; Andersen, R.J. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the Indonesian marine sponge *Acanthodendrilla* sp. *J. Nat. Prod.* 2004, 67, 2127–2129. [CrossRef] [PubMed]

79. Hamann, M.; Alonso, D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, M.; Castro, A.; Morales, S.; Navarro, M.; Monte-Millan, M.; Medina, M.; et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure activity relationship (SAR). Studies of the manzamine alkaloids. Potential for Alzheimer’s disease. *J. Nat. Prod.* 2007, 70, 1397–1405. [CrossRef] [PubMed]

80. Ang, K.; Holmes, M.; Higa, T.; Hamann, M.; Kara, U. In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. *Antimicrob. Agents Chemother.* 2000, 44, 1645–1649. [CrossRef] [PubMed]

81. Marion, F.; Williams, D.E.; Patrick, B.O.; Hollander, I.; Mallon, R.; Kim, S.C.; Roll, D.M.; Feldberg, L.; Van Soest, R.; Andersen, R.J. Liphagal, a selective inhibitor of PI3 kinase alpha isolated from the sponge *Aka coralliphaga*. Structure elucidation and biomimetic synthesis. *Org. Lett.* 2006, 8, 321–324. [CrossRef] [PubMed]
104. Ganesan, S.; Raja, S.; Sampathkumar, P.; Sivakumar, K.; Thangaradjou, T. Isolation and screening of α-glucosidase enzyme inhibitor producing marine actinobacteria. *Afr. J. Microbiol. Res.* **2011**, *5*, 3437–3445. [CrossRef]

105. Wahyudi, A.T.; Mubarik, N.R. Screening and characterization of protease inhibitors from marine bacteria associated with sponge *Jaspis* sp. *HAYATI J. Biosci.* **2010**, *4*, 173–178. [CrossRef]